NewEdge Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.39M | Sell |
13,031
-8,017
| -38% | -$1.48M | 0.01% | 1015 |
|
|
2025
Q4 | $3.7M | Buy |
21,048
+11,910
| +130% | +$1.95M | 0.01% | 786 |
|
|
2025
Q3 | $1.28M | Buy |
9,138
+6,465
| +242% | +$874K | 0.01% | 1257 |
|
|
2025
Q2 | $336K | Buy |
2,673
+316
| +13% | +$39.4K | ﹤0.01% | 1950 |
|
|
2025
Q1 | $323K | Sell |
2,357
-22
| -0.9% | -$3.15K | ﹤0.01% | 1848 |
|
|
2024
Q4 | $364K | Sell |
2,379
-22
| -0.9% | -$3.71K | ﹤0.01% | 1762 |
|
|
2024
Q3 | $465K | Sell |
2,401
-612
| -20% | -$128K | ﹤0.01% | 1518 |
|
|
2024
Q2 | $699K | Sell |
3,013
-358
| -11% | -$77.8K | 0.01% | 1231 |
|
|
2024
Q1 | $727K | Sell |
3,371
-3,168
| -48% | -$742K | 0.01% | 1155 |
|
|
2023
Q4 | $1.65M | Buy |
6,539
+3,172
| +94% | +$779K | 0.02% | 735 |
|
|
2023
Q3 | $865K | Buy |
3,367
+314
| +10% | +$84K | 0.01% | 925 |
|
|
2023
Q2 | $870K | Buy |
3,053
+745
| +32% | +$222K | 0.01% | 935 |
|
|
2023
Q1 | $642K | Sell |
2,308
-559
| -19% | -$155K | 0.01% | 1000 |
|
|
2022
Q4 | $759K | Buy |
2,867
+1,768
| +161% | +$499K | 0.02% | 611 |
|
|
2022
Q3 | $293K | Sell |
1,099
-6,359
| -85% | -$1.35M | ﹤0.01% | 1217 |
|
|
2022
Q2 | $1.52M | Buy |
+7,458
| New | +$1.52M | 0.03% | 514 |
|
|
2021
Q4 | – | Sell |
-1,205
| Closed | -$341K | – | 1639 |
|
|
2021
Q3 | $341K | Buy |
+1,205
| New | +$395K | 0.01% | 857 |
|
|
2020
Q4 | – | Sell |
-4,651
| Closed | -$1.32M | – | 986 |
|
|
2020
Q3 | $1.32M | Buy |
4,651
+159
| +4% | +$44.3K | 0.05% | 315 |
|
|
2020
Q2 | $1.2M | Buy |
4,492
+276
| +7% | +$83K | 0.05% | 315 |
|
|
2020
Q1 | $1.33M | Sell |
4,216
-441
| -9% | -$134K | 0.06% | 257 |
|
|
2019
Q4 | $1.38M | Sell |
4,657
-209
| -4% | -$58K | 0.05% | 300 |
|
|
2019
Q3 | $1.08M | Buy |
+4,866
| New | +$1.13M | 0.05% | 329 |
|
|
2019
Q1 | – | Sell |
-790
| Closed | -$238 | – | 671 |
|
|
2018
Q4 | $238 | Sell |
790
-109
| -12% | -$34.8K | 0.02% | 545 |
|
|
2018
Q3 | $318K | Sell |
899
-485
| -35% | -$167K | 0.02% | 476 |
|
|
2018
Q2 | $409 | Sell |
1,384
-55
| -4% | -$15.5K | 0.04% | 342 |
|
|
2018
Q1 | $384K | Buy |
+1,439
| New | +$447K | 0.04% | 308 |
|
|
2017
Q3 | – | Sell |
-531
| Closed | -$145K | – | 440 |
|
|
2017
Q2 | $145K | Buy |
+531
| New | +$140K | 0.03% | 360 |
|
Other funds holding BIIB
VCM
VPM
NewEdge Advisors's BIIB Position: Q1 2026 in Review
NewEdge Advisors reduced its Biogen (BIIB) stake by 38% in Q1 2026, selling an estimated $1.48M and leaving 13,031 shares worth $2.39M. The position accounts for 0.01% of the portfolio, ranked #1015.
NewEdge Advisors first reported a position in BIIB in Q2 2017 and has held it in 27 quarters since. The position peaked at $3.7M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- NewEdge Advisors held 13,031 shares of Biogen worth $2.39M as of Q1 2026.
- NewEdge Advisors sold 8,017 Biogen shares in Q1 2026, an estimated $1.48M.
- Biogen made up 0.01% of NewEdge Advisors's portfolio in Q1 2026, its #1015 holding.
- NewEdge Advisors first reported a position in Biogen in Q2 2017 and has held it in 27 quarters since.
- NewEdge Advisors's Biogen position peaked at $3.7M in Q4 2025.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.